You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 14, 2025

Details for New Drug Application (NDA): 020486

✉ Email this page to a colleague

NDA 020486 describes VANCERIL DOUBLE STRENGTH, which is a drug marketed by Schering and is included in one NDA. Additional details are available on the VANCERIL DOUBLE STRENGTH profile page.

The generic ingredient in VANCERIL DOUBLE STRENGTH is beclomethasone dipropionate. There are twenty drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the beclomethasone dipropionate profile page.

Summary for 020486

Tradename:	VANCERIL DOUBLE STRENGTH
Applicant:	Schering
Ingredient:	beclomethasone dipropionate
Patents:	0

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	AEROSOL, METERED;INHALATION			Strength	0.084MG/INH
Approval Date:	Dec 24, 1996	TE:		RLD:	No

Expired US Patents for NDA 020486

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Schering	VANCERIL DOUBLE STRENGTH	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020486-001	Dec 24, 1996	4,364,923	⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.